Literature DB >> 8737054

Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal.

M J Garrido1, R Jiminez, E Gomez, R Calvo.   

Abstract

The effect of spontaneous withdrawal on alpha 1-acid glycoprotein (AAG) levels and methadone protein binding has been studied in the rat. Animals were made physically dependent on morphine by providing morphine HCl in drinking water for three weeks. The natural opiate withdrawal was induced in rats by substituting the morphine solution with drinking water. The severity of the abstinence syndrome was assessed at various time intervals. After 12 h of withdrawal, the animals showing abstinence signs and low morphine levels were injected with intravenous methadone (0.35 mg kg-1) and the analgesic effect was measured by the tail-flick method and compared with animals receiving water. The oral administration of morphine produced an increase in AAG levels from 0.64 +/- 0.05 g L-1 in control animals to 1.47 +/- 0.92 g L-1 in experimental animals at the point of withdrawal and 1.21 +/- 0.09 g L-1 24 h after withdrawal. The percentage of methadone unbound was significantly lower in morphine-treated than in control animals. A significant correlation between AAG levels and percentage of methadone bound was observed. A parallel analgesic effect after intravenous methadone, as measured by AUC in the tail-flick test, was less in abstinence animals than in control (287.6 +/- 24.8 compared with 401.0 +/- 37.06s min). We suggest that in the withdrawal syndrome an adjustment of methadone dose may be necessary because of changes in protein binding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737054     DOI: 10.1111/j.2042-7158.1996.tb05917.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Against Repurposing Methadone for Glioblastoma Therapy.

Authors:  Tatjana Vatter; Lukas Klumpp; Katrin Ganser; Nicolai Stransky; Daniel Zips; Franziska Eckert; Stephan M Huber
Journal:  Biomolecules       Date:  2020-06-17

6.  Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of methadone in a sample of Iranian (mazandarani) opiate users undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Rasa Hosseinzadeh; Abolhassan Hamidikenari; Mehran Zarghami; Nargess Lamsehchi; Mohammad-Reza Rafati
Journal:  Iran J Psychiatry Behav Sci       Date:  2011
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.